Yüklüyor......
Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study
BACKGROUND: Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for gastric cancer (GC) reduces cancer recurrence and improves survival. S‐1 plus oxaliplatin (SOX) is well‐tolerated and effective against advanced GC, and also be used widely in adjuvant treatment. However, data comparing SOX an...
Kaydedildi:
| Yayımlandı: | Asia Pac J Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7318315/ https://ncbi.nlm.nih.gov/pubmed/32077628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13321 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|